Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR2 | O43603 | 1/20 | 0.43 |
| ▸ | GALR1 | P47211 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.42 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 4/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1033667 | 0.90 | GALR2 (0.54) | GALR2GALR1GABBR2GABBR1AXL | |
| SCHEMBL1032767 | 0.90 | GRM5 (0.43) | POLBMAPTGABBR2GABBR1KDM4E | |
| SCHEMBL1032768 | 0.90 | GRM5 (0.43) | POLBMAPTGABBR2GABBR1KDM4E | |
| SCHEMBL12125236 | 0.90 | GRM5 (0.43) | POLBMAPTGABBR2GABBR1KDM4E | |
| SCHEMBL1034596 | 0.83 | GABBR2 (0.62) | GALR2GALR1MAPTGABBR2GABBR1 | |
| SCHEMBL1034806 | 0.83 | KDM4E (0.49) | GALR2GALR1POLBMAPTGABBR2 | |
| SCHEMBL1033079 | 0.82 | KDM4E (0.50) | GALR2GALR1POLBMAPTGABBR2 | |
| SCHEMBL1074812 | 0.81 | GABBR2 (0.41) | GABBR2GABBR1ALDH1A1 | |
| SCHEMBL1028883 | 0.81 | GALR2 (0.44) | GALR2GALR1GABBR2GABBR1AXL | |
| SCHEMBL1028884 | 0.81 | GALR2 (0.44) | GALR2GALR1GABBR2GABBR1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010068863-A2 | PYRIMIDINE COMPOUNDS AND METHODS OF MAKING AND USING SAME | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| US-8513242-B2 | Pyrimidine compounds and methods of making and using same | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CYSTIC FIBROSIS FOUNDATION | 2011-11-17 | — | — | US | disclosed |
| WO-2011008931-A2 | ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010068863-A2 | PYRIMIDINE COMPOUNDS AND METHODS OF MAKING AND USING SAME | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CFTR, GPR17, TYMS | GALR2 4500/4885GALR1 4245/4885POLB 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.